MET and non-small cell lung carcinoma: MSC2156119J in combination with gefitinib in subjects with MET positive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation and having acquired resistance to first-line gefitinib